Published in Bull Cancer on July 01, 2011
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol (2006) 4.87
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
[Evaluating the benefits of mammographic breast cancer screening]. Orv Hetil (2010) 2.02
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol (2012) 1.91
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst (2006) 1.86
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol (2013) 1.77
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer (2007) 1.73
An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg (2003) 1.71
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol (2009) 1.68
Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol (2009) 1.68
Oxaliplatin-related side effects: characteristics and management. Semin Oncol (2002) 1.59
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol (2005) 1.56
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial. BMC Cancer (2012) 1.40
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol (2003) 1.40
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer (2009) 1.39
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.34
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol (2011) 1.31
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol (2007) 1.27
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm (2009) 1.22
Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res (2006) 1.20
Allergic rhinitis: a disease remodeling the upper airways? J Allergy Clin Immunol (2004) 1.18
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol (2004) 1.16
Wandering spleen in children: multicenter retrospective study. J Pediatr Surg (2010) 1.16
Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol (2005) 1.16
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med (2011) 1.13
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat (2010) 1.13
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys (2010) 1.12
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer (2002) 1.11
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol (2010) 1.11
Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome. J Thorac Oncol (2007) 1.10
Re: clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst (2012) 1.08
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs (2011) 1.07
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol (2003) 1.06
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res (2012) 1.06
Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06
Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer (2002) 1.06
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res (2011) 1.06
CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist (2009) 1.05
Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res (2007) 1.05
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol (2007) 1.03
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev (2011) 1.02
Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer (2011) 1.02
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med (2010) 1.01
First case of feline spongiform encephalopathy in a captive cheetah born in France: PrP(sc) analysis in various tissues revealed unexpected targeting of kidney and adrenal gland. Histochem Cell Biol (2003) 1.00
Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging (2009) 1.00
Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics (2006) 1.00
Cancer screening in France: subjects' and physicians' attitudes. Cancer Causes Control (2007) 0.99
Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer (2005) 0.98
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat (2013) 0.97
Pregnancy-associated breast cancers: do they differ from other breast cancers in young women? Breast (2012) 0.96
A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer (2010) 0.96
Esophageal atresia: data from a national cohort. J Pediatr Surg (2013) 0.95
Biology of cancer and aging: a complex association with cellular senescence. J Clin Oncol (2014) 0.95
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer (2003) 0.95
High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer (2005) 0.95
Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer (2002) 0.95
Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer (2004) 0.95
Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer (2005) 0.94
3D-conformal accelerated partial breast irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity. Radiat Oncol (2009) 0.94
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer (2008) 0.93
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer (2011) 0.92
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas (2002) 0.92
Congenital megaprepuce: a 12-year experience (52 cases) of this specific form of buried penis. J Pediatr Urol (2012) 0.91
Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance. Cancer (2003) 0.91
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol (2012) 0.91